TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02359292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 HS 200/6/25 pMDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 MS 100/6/25 pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 HS 200/6/25 pMDI + Charcoal Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF 5993 MS 100/6/25 pMDI + Charcoal Block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pMDI
Study: NCT00000410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diskectomy
Description: The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical treatments
Description: Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
Study: NCT01280929

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Panretinal Photocoagulation (PRP)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreous injection of ranibizumab
Study: NCT03427372

Intervention type: BEHAVIORAL
Intervention: anxiety scale, depression scale
Description: post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale

Intervention type: BEHAVIORAL
Intervention: anxiety scale, depression scale
Description: post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
Study: NCT02197546

Intervention type: OTHER
Group type: OTHER
Intervention: Acupuncture & acupressure
Description: Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
Study: NCT05846009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR442501
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT02752412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100 (HOE901)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01116089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bramitob® administered by PARI LC® PLUS nebulizer
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bramitob® administered by PARI eFlow® rapid electronic nebulizer
Description: (tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
Study: NCT03324165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proposed Algorithm
Description: Proposed algorithm that uses Alvarado Score to guide CT utilization
Study: NCT05631080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Endoscpic enucleation of the Prostate
Description: Transurethral endoscopic enucleation of the prostate adenoma
Study: NCT02841618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Linoleic Acid Healthy Cookies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High Oleic Acid Healthy Cookies
Study: NCT04096560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: TAK-994 tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-994 placebo-matching tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-994 placebo-matching tablets.
Study: NCT04412096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% ophthalmic solution
Description: 1 drop BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: 1 drop QD
Study: NCT01948011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril suspension
Description: Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
Study: NCT02791334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV
Study: NCT01948011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril granules
Description: Racecadotril granules at 60mg. Single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril granules
Description: Racecadotril granules at 60mg. Single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril granules
Description: Racecadotril granules at 60mg. Single oral dose.
Study: NCT02878239

Intervention type: OTHER
Intervention: Steps 1
Description: Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.

Intervention type: OTHER
Intervention: Steps 1
Description: Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.

Intervention type: OTHER
Intervention: Steps 1
Description: Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.

Intervention type: OTHER
Intervention: Steps 2
Description: Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
Study: NCT02791334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Merestinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV
Study: NCT04213794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Undergo HIPEC with doxorubicin and cisplatin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Undergo cytoreduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Undergo HIPEC with doxorubicin and cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: Undergo HIPEC with doxorubicin and cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04502602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib 160 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib 160 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib 200 mg
Description: Determined RP2D dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 100 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg
Description: Escalating doses to determine recommended phase 2 dose (RP2D)
Study: NCT03716830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: Participants will receive real acupuncture treatment.
Study: NCT04502602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg
Description: Phase 1: Escalating doses to determine recommended phase 2 dose (RP2D)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib at RP2D
Description: Phase 1b: Determined dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib at RP2D
Description: Phase 1b: Determined dose
Study: NCT03698773

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Access to routine information
Description: Access to routine pain-control information
Study: NCT03716830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: verum acupuncture
Description: Participants will receive real acupuncture treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham acupuncture
Description: Participants will receive sham acupuncture treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Participants will receive sham acupuncture treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: Participants will receive real transcranial direct current stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real tDCS
Description: Participants will receive real transcranial direct current stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants will receive sham transcranial direct current stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS
Description: Participants will receive sham transcranial direct current stimulation.
Study: NCT00983255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA for injection, 200 mg/vial
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA for injection, 200 mg/vial
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA for injection, 200 mg/vial
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA for injection, 200 mg/vial
Description: TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 \& 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA tablets
Description: TR-701 FA will be given once orally as a 200 mg tablet in Part C.
Study: NCT04854707

Intervention type: DRUG
Intervention: Follitropin Alfa
Description: Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH or agonist of GnRH.

Intervention type: DRUG
Intervention: Follicle Stimulating Hormone/Luteinizing Hormone
Description: Subcutaneous injection of follitropin alpha biosimilar, with daily dose 100-300 IU for at least 5 days, than added another gonadotropin for a maximum of 10 days, using antagonists of GnRH or agonist of GnRH.

Intervention type: DRUG
Intervention: Follitropin Alfa
Description: Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using antagonists of GnRH only for suppression.

Intervention type: DRUG
Intervention: Follitropin Alfa
Description: Subcutaneous injection of follitropin alpha biosimilar only, with daily dose 100-300 IU for 10 days, maximum of 15 days, using agonists of GnRH only for suppression.

Intervention type: DRUG
Intervention: Follicle Stimulating Hormone/Luteinizing Hormone
Description: Overall ovarian stimulation protocols with follitropin alpha biosimilar for at least 5 days+other recombinant and menotropins and short (antagonists of GnRH) or long protocol (agonist of GnRH).
Study: NCT03698773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to website
Description: Access to informational website: thepainlesspush.com
Study: NCT00532779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 16 mg/Bupropion SR 360 mg /day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone SR 32 mg/Bupropion SR 360 mg /day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Ancillary therapy
Description: Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
Study: NCT01937546

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary delivery of anterior shoulder

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary delivery posterior shoulder
Study: NCT00958698

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychosocial Assessment and Care
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02332655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed.
Study: NCT00864084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
Study: NCT04482101

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal obturation
Description: Root canal filling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Root canal obturation
Description: Root canal filling
Study: NCT03855930

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).

Intervention type: DIAGNOSTIC_TEST
Intervention: functional MRI
Description: During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
Study: NCT04874701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsimax
Description: Capsimax, 2 capsules per day, for 12 weeks Medicinal ingredient: Capsicum annuum Quantity (per capsule): 100.0 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy restriction
Description: Personalised diet plan targeting a 500 kcal/day energy restriction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy restriction
Description: Personalised diet plan targeting a 500 kcal/day energy restriction
Study: NCT01843660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl-Paracetamol
Description: Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram \[mg\] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.